Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum
Part of paid clinical trials in Pittsburgh, Pennsylvania.
- Sponsor
- University of Pittsburgh
- Study ID
- NCT01042548
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The current study is a case control study involving comparisons of tissue interstitial fluid from breast cancer and adjacent non-cancerous tissue as well as that from benign breast lesion and its adjacent non-diseased tissue for a distinguishable breast cancer profile. The purpose of this research is to collect fresh breast nodule/cancer and surrounding non-cancerous tissue for proteomic studies of the interstitial fluid to identify a profile distinguishing breast cancer which will also permit future research on stored interstitial fluid, blood or tissue samples. Specific markers identified from interstitial fluid study will be investigated in blood samples to develop serum markers for breast cancer diagnosis and prognosis. Additionally, we will perform both prospective and retrospective research on breast cancer involving clinical, demographic, epidemiologic information, treatment, follow-up and outcomes on breast nodule/cancer cases collected.
Key Dates
- Start date
- Feb 3, 2010
- Status verified
- May 2026
- Primary completion
- Apr 30, 2030
- Completion
- Apr 30, 2030
Study Design
- Enrollment
- 300 participants (estimated)
Central Contacts
- Laura Chiesa412-831-1320
- Min Sun, MD, PhD412-781-3744
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UPMC St. Margaret | Pittsburgh | Pennsylvania | 15215 | Min Sun, MD, PhD Min Sun, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Pittsburgh, PA
Related Studies
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- Cardiotoxicity of Cancer Therapy (CCT)Enrolling By Invitation · Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania
- PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast CancerRecruiting · Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Birmingham, Alabama